# US 2022/0033404 A1 · Treatment of infections of toxoplasma gondii and closely related parasites

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033404 A1
- Document ID: US20220033404A1
- Status: Published application
- Kind: A1
- Application number: 17/276,997
- Filed: 2019-09-18
- Published: 2022-02-03
- Earliest claimed: 2018-09-18
- Assignees: Washington University; The Broad Institute, Inc.; President and Fellows of Harvard College
- Applicants: Washington University; The Broad Institute, Inc.; President and Fellows of Harvard College
- Inventors: L. DAVID SIBLEY; JOSHUA RADKE; EAMON COMER; MARSHALL MORNINGSTAR; BRUNO MELILLO
- Web page: https://patentgrep.com/patent/US20220033404A1

## CPC

- A61K 31/397: having four-membered rings, e.g. azetidine
- C07D 487/04: Ortho-condensed systems
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 33/10: Anthelmintics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds useful for the treatment of diseases caused by infections of T. gondii, and closely related parasites. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compositions including veterinary compositions and may be used in methods of treatment and/or prophylaxis of disease.

## Claims

### Claim 1

A method of treatment or prophylaxis of Toxoplasma gondii infection or infection caused by a parasite closely related to Toxoplasma gondii in a subject in need thereof comprising administering to said subject a compound having the structure of formula (I):
wherein the dashed bond () may be a single or double bond;
m is 0 (i.e., it is a bond) or 1;
n is 0, 1 or 2;
A is CH or N;
L1 is absent (i.e., it is a bond), or —C≡C—;
L2 is absent, alkylene, —C(O)NR—; —SO2—, or —C(O)—;
L3 is absent, alkylene, or heteroalkylene;
R1 is hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, or cycloalkyl, and R1 is optionally substituted;
R2 is perfluoroalkyl, aryl, arylalkyl, alkyl, heteroaryl, or cycloalkyl, and R2 is optionally substituted;
R3 is hydrogen, —OH, —OR, —N(R)S(O)2R, —C(O)R, —NR, or heterocyclyl, and R3 is optionally substituted;
R4 is hydrogen or —CH2OH;
R5 and R6 are independently selected from hydrogen and OH; and
R is independently selected at each occurrence from hydrogen and lower alkyl, wherein R is optionally substituted.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said compound has the structure of formula (II):
wherein n is 0 (i.e. it is a bond) or 1;
L2 is absent or —C(O)NH—;
L3 is absent or —CH2—
R1 is aryl, heteroaryl, or cycloalkyl group, and R1 is optionally substituted with —CN;
R2 is aryl, heteroaryl, or cycloalkyl, and R2 is optionally substituted with halogen or —OR;
R3 is hydrogen, —OH, —OR, —N(R)S(O)2R, —NR, or heterocyclyl, and R3 is optionally substituted with —R;
R4 is hydrogen or —CH2OH;
R5 and R6 are independently selected from hydrogen and OH; and
R is independently selected at each occurrence from alkyl or cycloalkyl and R is optionally substituted with halogen, —OH, or —COOH.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said compound has the structure of formula (IIa):

### Claim 4 (depends on 1)

The method according to claim 1, wherein L2 is —C(O)NH— and R2 is phenyl optionally substituted with halogen or —OR.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said compound has the structure of formula (IIIa):

### Claim at position 6

6-9. (canceled)

### Claim 10 (depends on 1)

The method according to claim 1, wherein said compound has the structure of formula (IV):
wherein R1 is aryl, heteroaryl, or cycloalkyl, and R1 is optionally substituted with —CN;
R2 is aryl, heteroaryl, or cycloalkyl, and R2 is optionally substituted with halogen or —OR;
R3 is —OR, —N(R)S(O)2R, or heterocyclyl;
R4 is hydrogen or —CH2OH; and
R is independently selected at each occurrence from alkyl or cycloalkyl, and R is optionally substituted with halogen, —OH, or —COOH.

### Claim 11 (depends on 1)

The method according to claim 1, wherein said compound has the structure:

### Claim 12 (depends on 1)

The method according to claim 1, wherein said subject is human.

### Claim 13 (depends on 1)

The method according to claim 1, wherein said subject is a mouse, rat, cat, dog, chicken, turkey, rabbit, non-human primate, lizard, gecko, cow, calf, sheep, goat, lamb, horse, foal, pig, or piglet.

### Claim 14 (depends on 1)

The method according to claim 1, wherein said compound is co-administered with one or more antibiotics selected from pyrimethamine, sulfadiazine, and clindamycin.

### Claim 15 (depends on 1)

The method according to claim 1, wherein said infection is caused from a parasite closely related to Toxoplasma gondii selected from Sarcocystis neurona or Neospora caninum.

### Claim 16 (depends on 1)

The method according to claim 1, wherein said infection is caused from Toxoplasma gondii.

### Claim 17

A compound having the structure of formula (IV):
wherein R1 is aryl, heteroaryl, or cycloalkyl optionally substituted with —CN;
R2 is aryl, heteroaryl, or cycloalkyl optionally substituted with halogen or —OR;
R3 is —OR, —N(R)S(O)2R, or heterocyclyl;
R4 is hydrogen or —CH2OH; and
R is independently selected at each occurrence from alkyl or cycloalkyl optionally substituted with halogen, —OH, or —COOH.

### Claim at position 15

18-19. (canceled)

### Claim 20 (depends on 17)

The compound according to claim 17, wherein said compound has the structure:

### Claim 21

A compound having the structure:

### Claim 22 (depends on 17)

A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound according to claim 17, or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 23 (depends on 22)

The pharmaceutical composition according to claim 22, formulated as a veterinary composition.

### Claim 24 (depends on 22)

The pharmaceutical composition according to claim 22, wherein said compound is present in an effective amount to inhibit infection of Toxoplasma gondii, Sarcocystis neurona, or Neospora caninum in a subject.

### Claim at position 21

25-26. (canceled)

### Claim 27 (depends on 22)

The pharmaceutical composition according to claim 22, wherein said subject is human.

### Claim 28 (depends on 22)

The pharmaceutical composition according to claim 22, wherein said composition further comprises one or more antibiotics selected from pyrimethamine, sulfadiazine, clindamycin, and mirincamycin.
